Prostate cancer drug given initial 'no' for NHS in England

June 8, 2018, Cancer Research UK
Prostate cancer drug given initial ‘no’ for NHS in England
Credit: Cancer Research UK

A prostate cancer drug has been provisionally rejected as a first-line treatment on the NHS in England.

The draft recommendation from the National Institute for Health and Care Excellence (NICE) means abiraterone (Zytiga) won't be made routinely available for men with newly diagnosed that has spread to other parts of the body.

As it stands, the NHS in England can only prescribe abiraterone for these men once standard hormone treatment or chemotherapy has failed.

Results from recent clinical trials have shown that giving abiraterone alongside steroids and as a first-line treatment can reduce the chance of the cancer coming back and improve survival compared to hormone therapy alone.

Sir Harpal Kumar, Cancer Research UK's chief executive, called the decision "disappointing". "Two published last year provided compelling evidence of the huge potential benefit of abiraterone for these patients," he said.

What does the decision mean?

NICE published its draft recommendation this week, rejecting abiraterone as a first-line therapy. The committee concluded they couldn't accurately estimate the drug's cost effectiveness based on the data submitted.

The drug's manufacturer, Janssen, can now submit additional data, which will be reviewed later this summer before a final decision is reached.

A NICE spokesperson told The Telegraph : "We understand that some men with prostate will be disappointed by today's news.

"However, we can only recommend drugs that are clinically effective and show value for money compared to current treatment options. In this case, has fallen short."

Kumar urged NICE and Janssen to work together quickly to provide the information that will allow the drug to be recommended.

Explore further: Adding abiraterone to standard treatment improves prostate cancer survival by 40 percent

Related Stories

Adding abiraterone to standard treatment improves prostate cancer survival by 40 percent

June 3, 2017
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one of the largest ever clinical trials for prostate cancer presented at the ...

Trial shows responses to abiraterone acetate in some prostate cancer patients with initial hormone induction failure

April 5, 2017
Patients with metastatic prostate cancer whose PSA levels remain high despite initial hormone treatments have historically had poor prognosis, with survival typically in the 1-2 year range. Results of a 40-person clinical ...

Treatment extends life for some with advanced prostate cancer

June 3, 2017
Adding a new anti-hormonal drug to the standard treatment for advanced prostate cancer has been shown to reduce the risk of dying by almost 40 percent, according to two studies published Saturday.

Tests identify who would benefit from advanced prostate cancer therapies

June 5, 2018
Two blood tests can predict which subset of men with advanced prostate cancer will likely not benefit from anti-androgen therapies, providing doctors and patient added clarity on treatment options, according to a study led ...

Prostate drug decision highlights urgent need for reform

August 18, 2014
Just a week after the controversy over breast cancer drug Kadcyla, the inflexibilities within the UK's disparate drug approval systems have been pulled into sharp focus once again.

Abiraterone delays metastatic prostate cancer growth by 18 months, extends survival

June 5, 2017
Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 ...

Recommended for you

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.